ARS Pharmaceuticals develops treatments for severe allergic reactions, notably an epinephrine nasal spray designed as a needle-free alternative to auto-injectors. Its lead product targets emergency use in anaphylaxis for patients and caregivers who may prefer or better tolerate a nasal route. The business model centers on specialty pharmaceuticals for allergy emergencies rather than broad primary-care drug portfolios.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 15.7 | — | -44.9 | — |
| Q3 2025 | 32.5 | — | -51.1 | — |
| Q4 2025 | 28.1 | — | -41.3 | — |
| Q1 2026 | 22.7 | — | -60.6 | — |
| Q2 2026 | 33.7 | 114.2% | -62.3 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Starz Entertainment Corp. (STRZ), Teamshares Inc. (TMS), Investar Holding Corporation (ISTR), ATN International, Inc. (ATNI), mF International Limited (MFI), Berto Acquisition Corp. (TACO)